Epizyme falls on DLBCL discontinuations for tazemetostat

Epizyme Inc. (NASDAQ:EPZM) lost $3.10 (24%) to $9.90 on Thursday after discontinuing development of tazemetostat both as monotherapy and in combination with prednisolone to treat diffuse large B cell lymphoma. The news comes three

Read the full 344 word article

User Sign In